drugset / Trial / NCT06019000

Study of CYR-064 Versus Placebo in Patients.

NCT06019000 ↗

Phase 2 Completed 151 enrolled Cyrano Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.

Timeline

Start
2023-09-26
Primary completion
2025-11-11
Completion
2025-11-21

Outcome

Met primary endpoint

release “Trial met its primary safety and key prespecified secondary efficacy endpoints, supporting advancement into Phase 3 development in 2H 2026” cyranotherapeutics.com ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CYR-064 Unknown — Intranasal

Indications

No indication recorded.